<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2022-7.4.6</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-3644</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МОРФОЛОГИЯ, ФИЗИОЛОГИЯ И ПАТОФИЗИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MORPHOLOGY, PHYSIOLOGY AND PATHOPHYSIOLOGY</subject></subj-group></article-categories><title-group><article-title>Гормональные характеристики андрогенного статуса и их связь с антропометрическими и метаболическими показателями у мужчин в зависимости от тяжести течения гипертонической болезни</article-title><trans-title-group xml:lang="en"><trans-title>Hormonal characteristics of androgen status and their relationship with the anthropometric and metabolic parameter in men depending on the severity of hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8486-3185</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Янковская</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yankovskaya</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Янковская Светлана Валерьевна – аспирант, младший научный сотрудник лаборатории эндокринологии</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Svetlana V. Yankovskaya – Postgraduate Student, Junior Research Officer, Laboratory of Endocrinology</p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">svetlanaiankovskaia@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьминова</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzminova</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьминова Ольга Ивановна – старший научный сотрудник лаборатории эндокринологии</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Olga I. Kuzminova – Senior Research Officer, Laboratory of Endocrinology</p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">oikuzminova@frcftm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4579-425X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пинхасов</surname><given-names>Б. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Pinkhasov</surname><given-names>B. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пинхасов Борис Борисович – доктор медицинских наук, ведущий научный сотрудник лаборатории эндокринологии</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Boris B. Pinkhasov – Dr. Sc. (Med.), Leading Research Officer, Laboratory of Endocrinology</p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">pin@centercem.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лутов</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lutov</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лутов Юрий Владимирович – доктор медицинских наук, ведущий научный сотрудник лаборатории эндокринологии</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Yurij V. Lutov – Dr. Sc. (Med.), Leading Research Officer, Laboratory of Endocrinology</p><p>Timakova str. 2, Novosibirsk 630117</p></bio><email xlink:type="simple">yvl1308@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4534-7289</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Селятицкая</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Selyatitskaya</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Селятицкая Вера Георгиевна – доктор биологических наук, профессор, главный научный сотрудник лаборатории эндокринологии</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p><p> </p></bio><bio xml:lang="en"><p>Vera G. Selyatitskaya – Dr. Sc. (Biol.), Professor, Chief Research Officer, Laboratory of Endocrinology</p><p>Timakova str. 2, Novosibirsk 630117</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»</institution></aff><aff xml:lang="en"><institution>Federal Research Center of Fundamental and Translational Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>01</day><month>09</month><year>2022</year></pub-date><volume>7</volume><issue>4</issue><fpage>52</fpage><lpage>61</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Янковская С.В., Кузьминова О.И., Пинхасов Б.Б., Лутов Ю.В., Селятицкая В.Г., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Янковская С.В., Кузьминова О.И., Пинхасов Б.Б., Лутов Ю.В., Селятицкая В.Г.</copyright-holder><copyright-holder xml:lang="en">Yankovskaya S.V., Kuzminova O.I., Pinkhasov B.B., Lutov Y.V., Selyatitskaya V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/3644">https://www.actabiomedica.ru/jour/article/view/3644</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Согласно литературным данным, длительно существующая и плохо контролируемая гипертоническая болезнь (ГБ) приводит к поражению органов-мишеней, а в ряде случаев – к развитию ассоциированных клинических состояний, тяжесть которых у мужчин частично может быть обусловлена особенностями андрогенного статуса.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: выявить особенности гормональных показателей андрогенного статуса и их связь с антропометрическими и метаболическими характеристиками мужчин-пациентов терапевтической клиники в зависимости от тяжести течения ГБ.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовано 296 мужчин в возрасте 59,0 [54,0; 65,0] лет с подтверждённой ГБ. Всем участникам исследования в утреннее время натощак проводили антропометрию, определение показателей метаболического и андрогенного статусов, оценку коморбидной отягощённости. В зависимости от тяжести течения ГБ все пациенты были разделены на группы (Г): Г1 (n = 134) – пациенты с ГБ, не имеющие в анамнезе ишемической болезни сердца (ИБС) и/или острого нарушения мозгового кровообращения (ОНМК); Г2 (n = 162) – пациенты с ГБ, имеющие в анамнезе ИБС и/или ОНМК. Результаты. У пациентов Г2 с тяжёлым течением ГБ выявлено снижение уровней свободного тестостерона (Тсв.) и в большей степени – дегидроэпиандростерон-сульфата (ДГЭА-С), а также общего холестерина и липопротеидов высокой и низкой плотности. Проведённый корреляционный анализ выявил наличие статистически значимых обратных корреляционных связей уровней общего тестостерона (Тобщ.) и Тсв. с индексом массы тела, величиной отношения обхвата талии к обхвату бёдер; только уровня Тсв. – с наличием ИБС, хронической сердечной недостаточности (ХСН), нарушениями углеводного обмена и абдоминальным типом распределения жира, а уровня ДГЭА-С – с наличием ИБС и ХСН.</p></sec><sec><title>Выводы</title><p>Выводы. Снижение Тсв. и ДГЭА-С ассоциировано с ранним прогрессированием атеросклероза и риском развития ГБ-ассоциированных сердечно-сосудистых катастроф, что может утяжелять течение ГБ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. According to the literature data, long-term and poorly controlled hypertension (HTN) leads to target organs damage, and in some cases, to the development of associated diseases, the severity of which in men may be partly due to the characteristics of the androgenic status.</p></sec><sec><title>The aim</title><p>The aim: to reveal the features of hormonal indicators of androgen status and their relationship with the anthropometric and metabolic characteristics of the therapeutic clinic male patients, depending on the severity of HTN.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 296 men aged 59,0 [54,0; 65,0] years with confirmed HTN were examined. All study participants in the morning on an empty stomach underwent anthropometry, determination of metabolic and androgenic status, and assessment of comorbid burden. Depending on the severity of hypertension, all patients were divided into two groups (G): G1 (n = 134) – patients with hypertension without a history of coronary artery disease or stroke; G2 (n = 162) – patients with hypertension with a history of ischemic heart disease (IHD) and/or stroke.</p></sec><sec><title>Results</title><p>Results. In male patients of G2 with severe HTN, a decrease in the levels of free testosterone (FT) and, to a greater extent, dehydroepiandrosterone sulfate (DHEA-S), as well as total cholesterol, high and low density lipoproteins, was revealed. The correlation analysis performed revealed statistically significant negative correlations between the levels of total testosterone (TT) and FT with body mass index, the value of the ratio of waist circumference to hips, only the level of FT – with the presence of IHD, chronic heart failure (CHF), disorders of carbohydrate metabolism and abdominal type of fat distribution, and the level of DHEA-S – with the presence of IHD and CHF.</p></sec><sec><title>Conclusion</title><p>Conclusion. A decrease in FT and DHEA-S is associated with early progression of atherosclerosis and the risk of developing HTN-associated cardiovascular events, which can aggravate the course of HTN.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мужчины</kwd><kwd>гипертоническая болезнь</kwd><kwd>сердечно-сосудистая коморбидность</kwd><kwd>избыточная масса тела</kwd><kwd>абдоминальное ожирение</kwd><kwd>андрогенный статус</kwd><kwd>общий и свободный тестостерон</kwd><kwd>дегидроэпиандростерон-сульфат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>men</kwd><kwd>hypertension</kwd><kwd>cardiovascular comorbidity</kwd><kwd>overweight</kwd><kwd>abdominal obesity</kwd><kwd>androgen status</kwd><kwd>total and free testosterone</kwd><kwd>dehydroepiandrosterone sulfate</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено в рамках выполнения государственного задания учреждения. Работа выполнена с использованием оборудования ЦКП «Протеомный анализ», поддержанного финансированием Минобрнауки России (соглашение № 07515-2021-691).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю.А., Концевая А.В., Мырзаматова А.О., Муканеева Д.К., Худяков М.Б., Драпкина О.М. Экономический ущерб от артериальной гипертонии, обусловленный её вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2020; 16(3): 415-423. doi: 10.20996/1819-6446-2020-05-03</mixed-citation><mixed-citation xml:lang="en">Balanova YA, Kontsevaya AV, Myrzamatova AO, Mukaneeva DK, Khudyakov MB, Drapkina OM. Economic burden of hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020; 16(3): 415-423. (In Russ.). doi: 10.20996/18196446-2020-05-03</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Денисова А.Р., Солнцева Т.Д., Сивакова О.А., Чазова И.Е. Неконтролируемая артериальная гипертония: основные причины, особенности патогенеза и подходы к лечению. Системные гипертензии. 2021; 18(1): 13-18. doi: 10.26442/20750 82X.2021.1.200724</mixed-citation><mixed-citation xml:lang="en">Denisova AR, Solntseva TD, Sivakova OA, Chazova IE. Uncontrolled arterial hypertension: Main causes, features of pathogenesis and approaches to treatment. Systemic Hypertension. 2021; 18(1): 13-18. (In Russ.). doi: 10.26442/2075082X.2021.1.200724</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018; 14(3): 185-201. doi: 10.1038/nrneph.2017.189</mixed-citation><mixed-citation xml:lang="en">Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018; 14(3): 185-201. doi: 10.1038/nrneph.2017.189</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедева Н.Б., Гофман В.В. Взаимосвязь возрастного гипогонадизма с риском развития сердечно-сосудистых заболеваний. Фундаментальная и клиническая медицина. 2020; 5(2): 60-66. doi: 10.23946/2500-0764-2020-5-2-60-66</mixed-citation><mixed-citation xml:lang="en">Lebedeva NB, Hoffman VV. Age-related hypogonadism and cardiovascular disease risk. Fundamental and Clinical Medicine. 2020; 5(2): 60-66. (In Russ.). doi: 10.23946/2500-0764-2020-5-2-60-66</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Li X, Cai Z, Li H, Yang B. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019; 23(5): 607-618. do i: 10.1080/13685538.2018.1557139</mixed-citation><mixed-citation xml:lang="en">Zhang J, Li X, Cai Z, Li H, Yang B. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019; 23(5): 607-618. doi: 10.1080/13685538.2018.1557139</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Тюзиков И.А. Дегидроэпиандростерон у мужчин: потенциальные физиологические эффекты с позиции доказательной медицины. Эффективная фармакотерапия. 2020; 16(20): 44-51. doi: 10.33978/2307-3586-2020-16-20-44-51</mixed-citation><mixed-citation xml:lang="en">Tyuzikov IA. Dehydroepiandrosterone in men: a potential physiological effects from the standpoint of evidence-based medicine. Effective Pharmacotherapy. 2020; 16(20): 44-51. (In Russ.). doi: 10.33978/2307-3586-2020-16-20-44-51</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Park M, Kim S, Won Y. Relationship between testosterone deficiency and the cardiovascular risk factors, diabetes and hypertension. J Mens Health. 2020; 16(4): 97-109. doi: 10.31083/jomh.v16i4.328</mixed-citation><mixed-citation xml:lang="en">Park M, Kim S, Won Y. Relationship between testosterone deficiency and the cardiovascular risk factors, diabetes and hypertension. J Mens Health. 2020; 16(4): 97-109. doi: 10.31083/jomh.v16i4.328</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bianchi VE.Testosterone, myocardial function, and mortality.Heart Fail Rev. 2018; 23(5): 773-788. doi: 10.1007/s10741-018-9721-0</mixed-citation><mixed-citation xml:lang="en">Bianchi VE.Testosterone, myocardial function, and mortality. Heart Fail Rev. 2018; 23(5): 773-788. doi: 10.1007/s10741-018-9721-0</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Попов П.С., Курникова И.А., Торшин В.И., Малютина Н.Н. Состояние липидного обмена у пациентов, получающих андрогензаместительную терапию. Пермский медицинский журнал. 2020; 37(5): 20-26. doi: 10.17816/pmj37520-26</mixed-citation><mixed-citation xml:lang="en">Popov PS, Kournikova IA, Torshin VI, Malyutina NN. State of lipid metabolism in patients receiving androgen replacement therapy. Perm Medical Journal. 2020; 37(5): 20-26. (In Russ.). doi: 10.17816/pmj37520-26</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Зеленина Т.А., Салухов В.В., Земляной А.Б., Чебыкина О.Е. Заместительная гормональная терапия тестостероном у мужчин с сахарным диабетом 2 типа и нейропатией. Фарматека. 2021; 28(4): 55-61. doi: 10.18565/pharmateca.2021.4.55-60</mixed-citation><mixed-citation xml:lang="en">Zelenina TA, Salukhov VV, Zemlyanoy AB, Chebykina OE. Testosterone replacement therapy in men with type 2 diabetes mellitus and neuropathy. Farmateka. 2021; 28(4): 55-61. (In Russ.). doi: 10.18565/pharmateca.2021.4.55-60</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ghadimi R, Khalilipour A, Malekian N, Esmaili H, Hosseini SR, Bayani M. Serum testosterone and metabolic syndrome in old-aged males: preliminary findings of the AHAP cohort study. Rom JDiabetes Nutr Metab Dis. 2020; 27(3): 245-250. doi: 10.46389/rjd-2020-1036</mixed-citation><mixed-citation xml:lang="en">Ghadimi R, Khalilipour A, Malekian N, Esmaili H, Hosseini SR, Bayani M. Serum testosterone and metabolic syndrome in old-aged males: preliminary findings of the AHAP cohort study. Rom JDiabetes Nutr Metab Dis. 2020; 27(3): 245-250. doi: 10.46389/rjd-2020-1036</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедева Н.Б., Гофман В.В. Современные представления о роли возрастного гипогонадизма в развитии сердечнососудистых заболеваний. Терапевтический архив. 2021; 93(1): 79-83. doi: 10.26442/00403660.2021.01.200597</mixed-citation><mixed-citation xml:lang="en">Lebedeva NB, Hoffman VV. Current understanding of the role of age-related hypogonadism in the development of cardiovascular diseases. Terapevticheskii arkhiv. 2020; 93(1): 79-83. (In Russ.). doi: 10.26442/00403660.2021.01.200597</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bavishi A, Patel RB. Addressing comorbidities in heart failure: Hypertension, atrial fibrillation, and diabetes. Heart Fail Clin. 2020; 16(4): 441-456. doi: 10.1016/j.hfc.2020.06.005</mixed-citation><mixed-citation xml:lang="en">Bavishi A, Patel RB. Addressing comorbidities in heart failure: Hypertension, atrial fibrillation, and diabetes. Heart Fail Clin. 2020; 16(4): 441-456. doi: 10.1016/j.hfc.2020.06.005</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X, Wang L, Luo D, Zhang M, Chen S, Wang Y, et al. Effect of testosterone synthesis and conversion on serum testosterone levels in obese men. Horm Metab Res. 2018; 50(09): 661-670. doi: 10.1055/a-0658-7712</mixed-citation><mixed-citation xml:lang="en">Xu X, Wang L, Luo D, Zhang M, Chen S, Wang Y, et al. Effect of testosterone synthesis and conversion on serum testosterone levels in obese men. Horm Metab Res. 2018; 50(09): 661-670. doi: 10.1055/a-0658-7712</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pinkhasov BB, Selyatitskaya VG, Karapetyan AR, Astrakhantseva EL. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4(12A): 13811389. doi: 10.4236/health.2012.412A200</mixed-citation><mixed-citation xml:lang="en">Pinkhasov BB, Selyatitskaya VG, Karapetyan AR, Astrakhantseva EL. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4(12A): 13811389. doi: 10.4236/health.2012.412A200</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Мустафина С.В., Малютина С.К., Рымар О.Д., Щербакова Л.В., Bobak М., Воевода М.И. Эпидемиология ожирения и развитие нарушений углеводного обмена по данным проспективного исследования в Сибири. Ожирениеиметаболизм. 2015; 12(4): 24-28. doi: 10.14341/omet2015424-28</mixed-citation><mixed-citation xml:lang="en">Mustafina SV, Malyutina SK, Rymar OD, Shcherbakova LV, Bobak M, Voevoda MI. The epidemiology of obesity and the development of disorders of glucose metabolism according to a prospective study in Siberia. Obesity and Metabolism. 2015; 12(4): 24-28. (In Russ.). doi: 10.14341/omet2015424-28</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020; 35(4): 389-396. doi: 10.1097/HCO.0000000000000749</mixed-citation><mixed-citation xml:lang="en">Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020; 35(4): 389-396. doi: 10.1097/HCO.0000000000000749</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ke C, Zhu X, Zhang Y, Shen Y. Metabolomic characterization of hypertension and dyslipidemia. Metabolomics. 2018; 14(9): 117. doi: 10.1007/s11306-018-1408-y</mixed-citation><mixed-citation xml:lang="en">Ke C, Zhu X, Zhang Y, Shen Y. Metabolomic characterization of hypertension and dyslipidemia. Metabolomics. 2018; 14(9): 117. doi: 10.1007/s11306-018-1408-y</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. Diabetes care. 2017; 40(4): 529-537. doi: 10.2337/dc16-1958</mixed-citation><mixed-citation xml:lang="en">Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. Diabetes care. 2017; 40(4): 529-537. doi: 10.2337/dc16-1958</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020; 63(1): 10-21. doi: 10.1016/j.pcad.2019.11.009</mixed-citation><mixed-citation xml:lang="en">Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020; 63(1): 10-21. doi: 10.1016/j.pcad.2019.11.009</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019; 15(4): 531-541. doi: 10.1016/j.hfc.2019.06.007</mixed-citation><mixed-citation xml:lang="en">Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019; 15(4): 531-541. doi: 10.1016/j.hfc.2019.06.007</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dzeshka MS, Shantsila A, Shantsila E, Lip GY. Atrial fibrillation and hypertension. Hypertension. 2017; 70(5): 854-861. doi: 10.1161/HYPERTENSIONAHA.117.08934</mixed-citation><mixed-citation xml:lang="en">Dzeshka MS, Shantsila A, Shantsila E, Lip GY. Atrial fibrillation and hypertension. Hypertension. 2017; 70(5): 854-861. doi: 10.1161/HYPERTENSIONAHA.117.08934</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Selyatitskaya VG, Epanchintseva EA, Novikova EG, Shilina NI, Pinkhasov BB. Hormonal characteristics of androgen status in males of different age groups. Advances in Gerontology. 2020; 10(3): 210-214. doi: 10.1134/S2079057020030169</mixed-citation><mixed-citation xml:lang="en">Selyatitskaya VG, Epanchintseva EA, Novikova EG, Shilina NI, Pinkhasov BB. Hormonal characteristics of androgen status in males of different age groups. Advances in Gerontology. 2020; 10(3): 210-214. doi: 10.1134/S2079057020030169</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Salama N, Blgozah S. Serum estradiol levels in infertile men with non-obstructive azoospermia. Ther Adv Reprod Health. 2020; 14: 2633494120928342. doi: 10.1177/2633494120928342</mixed-citation><mixed-citation xml:lang="en">Salama N, Blgozah S. Serum estradiol levels in infertile men with non-obstructive azoospermia. Ther Adv Reprod Health. 2020; 14: 2633494120928342. doi: 10.1177/2633494120928342</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Van Hemelrijck M, Sollie S, Nelson WG, Yager JD, Kanarek NF, Dobs A, et al. Selenium and sex steroid hormones in a US nationally representative sample of men: A role for the link between selenium and estradiol in prostate carcinogenesis? Cancer Epidemiol Biomarkers Prev. 2019; 28(3): 578-583. doi: 10.1158/10559965.EPI-18-0520</mixed-citation><mixed-citation xml:lang="en">Van Hemelrijck M, Sollie S, Nelson WG, Yager JD, Kanarek NF, Dobs A, et al. Selenium and sex steroid hormones in a US nationally representative sample of men: A role for the link between selenium and estradiol in prostate carcinogenesis? Cancer Epidemiol Biomarkers Prev. 2019; 28(3): 578-583. doi: 10.1158/10559965.EPI-18-0520</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bellastella G, Menafra D, Puliani G, Colao A, Savastano S. How much does obesity affect the male reproductive function? Int JObes Suppl. 2019; 9(1): 50-64. doi: 10.1038/s41367-019-0008-2</mixed-citation><mixed-citation xml:lang="en">Bellastella G, Menafra D, Puliani G, Colao A, Savastano S. How much does obesity affect the male reproductive function? Int JObes Suppl. 2019; 9(1): 50-64. doi: 10.1038/s41367-019-0008-2</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В., Камалов А.А., Мкртумяни А.М. и др. Проект клинических рекомендаций «синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021; 18(4): 496-507. doi: 10.14341/omet12817</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mokrysheva NG, Melnichenko GA, Rozhivanov RV, Kamalov AA, Mkrtumyan AM, et al. Draft of Russian clinical practice guidelines“Male hypogonadism”. Obesityand Metabolism. 2021; 18(4): 496-507. (In Russ.). doi: 10.14341/omet12817</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Терещенко С.Н., Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 311-374. doi: 10.15829/1560-4071-2020-4083</mixed-citation><mixed-citation xml:lang="en">Tereshchenko SN, Galyavich AS, Uskach TM, Ageev FT, Arutyunov GP, Begrambekova YuL. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020; 25(11): 311-374. (In Russ.). doi: 10.15829/1560-4071-2020-4083</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2 типа у взрослых. Сахарныйдиабет. 2020; 23(S2): 4-102. doi: 10.14341/DM20202S</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AY, Shamkhalova MS, Sukhareva OYu, Galstyan GR, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020; 23(2S): 4-102. (In Russ.). doi: 10.14341/DM12507</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mannella P, Simoncini T, Caretto M, Genazzani AR. Dehydroepiandrosterone and cardiovascular disease. Vitam Horm. 2018; 108: 333-353. doi: 10.1016/bs.vh.2018.05.001</mixed-citation><mixed-citation xml:lang="en">Mannella P, Simoncini T, Caretto M, Genazzani AR. Dehydroepiandrosterone and cardiovascular disease. Vitam Horm. 2018; 108: 333-353. doi: 10.1016/bs.vh.2018.05.001</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshida S, Aihara KI, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010; 212(1): 310-315. doi: 10.1016/j.atherosclerosis.2010.05.011</mixed-citation><mixed-citation xml:lang="en">Yoshida S, Aihara KI, Azuma H, Uemoto R, SumitomoUeda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010; 212(1): 310-315. doi: 10.1016/j.atherosclerosis.2010.05.011</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wang F, He Y, Santos HO, Sathian B, Price JC, Diao J. The effects of dehydroepiandrosterone (DHEA) supplementation on body composition and blood pressure: A meta-analysis of randomized clinical trials. Steroids. 2020; 163: 108710. doi: 10.1016/j.steroids.2020.108710</mixed-citation><mixed-citation xml:lang="en">Wang F, He Y, Santos HO, Sathian B, Price JC, Diao J. The effects of dehydroepiandrosterone (DHEA) supplementation on body composition and blood pressure: A meta-analysis of randomized clinical trials. Steroids. 2020; 163: 108710. doi: 10.1016/j.steroids.2020.108710</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020; 153: 108507. doi: 10.1016/j.steroids.2019.108507</mixed-citation><mixed-citation xml:lang="en">Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020; 153: 108507. doi: 10.1016/j.steroids.2019.108507</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
